Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554137 | 0.90 | TSHR (0.40) | TSHRALDH1A1USP2HSD17B10HPGD | |
| SCHEMBL6555127 | 0.82 | ALDH1A1 (0.38) | TSHRALDH1A1USP2HSD17B10HPGD | |
| SCHEMBL11329200 | 0.81 | CRHR1 (0.39) | TSHRALDH1A1USP2HSD17B10HPGD | |
| SCHEMBL6555085 | 0.80 | ALDH1A1 (0.38) | TSHRALDH1A1USP2HSD17B10HPGD | |
| SCHEMBL6555894 | 0.79 | ALDH1A1 (0.37) | TSHRALDH1A1USP2HSD17B10HPGD | |
| SCHEMBL6553722 | 0.78 | CRHR1 (0.41) | TSHRALDH1A1HPGDMAPK1HTT | |
| SCHEMBL6555348 | 0.77 | POLB (0.48) | TSHRALDH1A1USP2HSD17B10POLB | |
| SCHEMBL6554158 | 0.74 | TSHR (0.46) | TSHRALDH1A1USP2POLB | |
| SCHEMBL2037646 | 0.73 | ALDH1A1 (0.43) | TSHRALDH1A1USP2HSD17B10HPGD | |
| SCHEMBL6555092 | 0.73 | ALDH1A1 (0.37) | TSHRALDH1A1USP2HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1234007-B1 | OLIGOMERIC METHINE DYES | CLARIANT FINANCE BVI LTD (VG) | 2004-02-18 | — | — | EP | disclosed |
| EP-1234007-A1 | OLIGOMERIC METHINE DYES | Clariant Finance (BVI) Limited (VG) | 2002-08-28 | — | — | EP | disclosed |
| US-20010012899-A1 | Oligomeric methine dyes | CLARIANT FINANCE ( BVI) LIMITED | 2001-08-09 | — | — | US | disclosed |
| WO-2001036543-A1 | OLIGOMERIC METHINE DYES | CLARIANT FINANCE (BVI) LIMITED (VG) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012899-A1 | Oligomeric methine dyes | INMT, DDT, DDC | TSHR 3212/4885ALDH1A1 604/4885USP2 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.